Hikal freezes in 5% upper circuit on development of Favipiravir API
Favipiravir is in various stages of clinical trials in many countries as an experimental treatment of Covid-19.15-05-2020
15-05-2020
HIKAL LTD. - 524735 - Intimation Under Regulation 30 Of SEBI LODR.
Intimation under Regulation 30 of SEBI LODR is attached.15-05-2020
HIKAL LTD. - 524735 - Compliance Under Regulation 40 (10) Of SEBI (LODR) Regulations 2015
Certificate Under Regulation 40 (10) of SEBI (LODR) Regulations 2015, enclosed11-05-2020
HIKAL LTD. - 524735 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance certificate under reg. 74(5) of SEBI (DP) Regulations, 201808-05-2020
HIKAL LTD. - 524735 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Sham WahalekarDesignation :- Company Secretary and Compliance Officer08-05-2020
HIKAL LTD. - 524735 - Shareholding for the Period Ended March 31, 2020
Hikal Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here04-05-2020
HIKAL LTD. - 524735 - Compliance Certificate For The Half Financial Year Ended On March 31, 2020
Compliance Certificate for the half financial year ended on March 31, 202004-05-2020
HIKAL LTD. - 524735 - Intimation Under Regulation 30 Of SEBI LODR.
Intimation under Regulation 30 of SEBI LODR.16-04-2020
HIKAL LTD. - 524735 - Intimation Under Regulation 30 SEBI LODR.
Intimation under Regulation 30 SEBI LODR.06-04-2020